MA41134B1 - Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales - Google Patents
Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections viralesInfo
- Publication number
- MA41134B1 MA41134B1 MA41134A MA41134A MA41134B1 MA 41134 B1 MA41134 B1 MA 41134B1 MA 41134 A MA41134 A MA 41134A MA 41134 A MA41134 A MA 41134A MA 41134 B1 MA41134 B1 MA 41134B1
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- treatment
- viral infections
- thiazolo
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Abstract
La présente invention concerne des composés de formule (i), dans laquelle r1, r2 et r3 sont tels que décrits ici, et leurs promédicaments ou leur sel, énantiomère ou diastéréoisomère pharmaceutiquement acceptables de ceux-ci, des compositions comprenant les composés ainsi que des procédés d'utilisation des composés comme agonistes de tlr7 pour le traitement et la prophylaxie d'infections virales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014093224 | 2014-12-08 | ||
CN2015086987 | 2015-08-14 | ||
PCT/EP2015/078439 WO2016091698A1 (fr) | 2014-12-08 | 2015-12-03 | Composés 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41134A MA41134A (fr) | 2017-10-18 |
MA41134B1 true MA41134B1 (fr) | 2021-03-31 |
Family
ID=54771116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41134A MA41134B1 (fr) | 2014-12-08 | 2015-12-03 | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales |
Country Status (32)
Country | Link |
---|---|
US (4) | US9441008B2 (fr) |
EP (1) | EP3230298B1 (fr) |
JP (1) | JP6817217B2 (fr) |
KR (2) | KR20230113824A (fr) |
CN (2) | CN107445980B (fr) |
AU (1) | AU2015359692B2 (fr) |
BR (1) | BR112017011941B1 (fr) |
CA (1) | CA2963717C (fr) |
CL (1) | CL2017001426A1 (fr) |
CR (1) | CR20170237A (fr) |
DK (1) | DK3230298T3 (fr) |
EA (1) | EA038744B1 (fr) |
ES (1) | ES2864223T3 (fr) |
HK (1) | HK1245764A1 (fr) |
HR (1) | HRP20210454T1 (fr) |
HU (1) | HUE053704T2 (fr) |
IL (1) | IL251285B (fr) |
LT (1) | LT3230298T (fr) |
MA (1) | MA41134B1 (fr) |
MX (1) | MX2017007044A (fr) |
MY (1) | MY194002A (fr) |
NZ (1) | NZ730398A (fr) |
PE (1) | PE20170679A1 (fr) |
PH (1) | PH12017501061B1 (fr) |
PL (1) | PL3230298T3 (fr) |
PT (1) | PT3230298T (fr) |
RS (1) | RS61612B1 (fr) |
SG (1) | SG11201704512PA (fr) |
SI (1) | SI3230298T1 (fr) |
TW (1) | TWI733656B (fr) |
UA (1) | UA124184C2 (fr) |
WO (1) | WO2016091698A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230113824A (ko) * | 2014-12-08 | 2023-08-01 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온화합물 |
EP3695837A1 (fr) * | 2015-03-16 | 2020-08-19 | F. Hoffmann-La Roche AG | Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b |
EP4001283A1 (fr) * | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
JP6839104B2 (ja) * | 2015-06-30 | 2021-03-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
MX2019008118A (es) * | 2017-01-06 | 2019-09-13 | Hoffmann La Roche | Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]. |
AU2018205994B2 (en) * | 2017-01-06 | 2021-09-09 | F. Hoffmann-La Roche Ag | Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds |
JP2021506827A (ja) | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
EP3759109B1 (fr) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
SG11202011667WA (en) | 2018-05-25 | 2020-12-30 | Primmune Therapeutics Inc | Tlr7 agonists |
WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途 |
EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 2’3’-環状ジヌクレオチドおよびそのプロドラッグ |
AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
CN114341185A (zh) | 2019-06-19 | 2022-04-12 | 希沃尔拜克治疗公司 | 抗间皮素抗体及其免疫缀合物 |
US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ, インコーポレイテッド | Hbvワクチン及びhbvを治療する方法 |
IL293293A (en) | 2019-11-26 | 2022-07-01 | Primmune Therapeutics Inc | tlr7 agonists |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
EP4081639A1 (fr) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Association pharmaceutique d'un oligonucléotide thérapeutique ciblant le vhb et un agoniste de tlr7 pour le traitement du vhb |
CA3163646A1 (fr) | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Association pharmaceutique d'agents antiviraux ciblant le vhb et/ou un modulateur immunitaire pour le traitement du vhb |
MX2022007911A (es) | 2019-12-24 | 2022-07-21 | Hoffmann La Roche | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. |
AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
EP4194006A1 (fr) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Vaccin à arnm comprenant un adjuvant permettant un contrôle cinétique |
WO2022031011A1 (fr) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Ensemble adjuvant à action cinétique |
EP4192955A1 (fr) | 2020-08-05 | 2023-06-14 | F. Hoffmann-La Roche AG | Traitement par oligonucléotides des patients atteints d'hépatite b |
JP2024518709A (ja) | 2021-04-10 | 2024-05-02 | プロファウンドバイオ ユーエス カンパニー | Folr1結合剤、そのコンジュゲートおよびこれを使用する方法 |
AU2022262644A1 (en) | 2021-04-23 | 2023-11-09 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
EP4359411A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
CN1233254A (zh) | 1996-10-16 | 1999-10-27 | Icn药品公司 | 嘌呤l-核苷、其类似物及其用途 |
EP1072607A3 (fr) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Analogues de nucléosides-L-purine et leurs utilisations |
US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
AU2004271972B2 (en) | 2003-09-05 | 2010-06-03 | Anadys Pharmaceuticals, Inc. | TLR7 ligands for the treatment of hepatitis C |
MY176938A (en) * | 2004-12-17 | 2020-08-27 | Anadys Pharmaceuticals Inc | 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof |
CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
EA200801404A1 (ru) | 2005-11-21 | 2008-10-30 | Анадис Фармасьютикалз, Инк. | Новый способ получения 5-амино-3н-тиазоло[4,5-d]пиримидин-2-она |
CL2007001427A1 (es) | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
BRPI0713680A2 (pt) * | 2006-06-22 | 2012-10-23 | Anadys Pharmaceuticals Inc | composto, composição farmacêutica e métodos de modulação das atividades imuno da citocina, de tratamento de infecção de vìrus da hepatite c em paciente e de tratamento de desordem de proliferação relacionada em mamìfero carecido do mesmo |
DE602007012881D1 (en) | 2006-07-18 | 2011-04-14 | Anadys Pharmaceuticals Inc | Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen |
BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
US20110166092A1 (en) * | 2007-08-20 | 2011-07-07 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
KR20230113824A (ko) | 2014-12-08 | 2023-08-01 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온화합물 |
EP3695837A1 (fr) | 2015-03-16 | 2020-08-19 | F. Hoffmann-La Roche AG | Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b |
EP4001283A1 (fr) | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
JP6839104B2 (ja) | 2015-06-30 | 2021-03-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン |
-
2015
- 2015-12-03 KR KR1020237024143A patent/KR20230113824A/ko not_active Application Discontinuation
- 2015-12-03 AU AU2015359692A patent/AU2015359692B2/en active Active
- 2015-12-03 PE PE2017000551A patent/PE20170679A1/es unknown
- 2015-12-03 UA UAA201706823A patent/UA124184C2/uk unknown
- 2015-12-03 HU HUE15804128A patent/HUE053704T2/hu unknown
- 2015-12-03 WO PCT/EP2015/078439 patent/WO2016091698A1/fr active Application Filing
- 2015-12-03 RS RS20210297A patent/RS61612B1/sr unknown
- 2015-12-03 CA CA2963717A patent/CA2963717C/fr active Active
- 2015-12-03 EA EA201791011A patent/EA038744B1/ru unknown
- 2015-12-03 CR CR20170237A patent/CR20170237A/es unknown
- 2015-12-03 MX MX2017007044A patent/MX2017007044A/es unknown
- 2015-12-03 SG SG11201704512PA patent/SG11201704512PA/en unknown
- 2015-12-03 CN CN201710845723.5A patent/CN107445980B/zh active Active
- 2015-12-03 KR KR1020177015128A patent/KR102557560B1/ko active IP Right Grant
- 2015-12-03 PT PT158041285T patent/PT3230298T/pt unknown
- 2015-12-03 BR BR112017011941-2A patent/BR112017011941B1/pt active IP Right Grant
- 2015-12-03 NZ NZ730398A patent/NZ730398A/en unknown
- 2015-12-03 US US14/958,619 patent/US9441008B2/en active Active
- 2015-12-03 EP EP15804128.5A patent/EP3230298B1/fr active Active
- 2015-12-03 ES ES15804128T patent/ES2864223T3/es active Active
- 2015-12-03 DK DK15804128.5T patent/DK3230298T3/da active
- 2015-12-03 JP JP2017548325A patent/JP6817217B2/ja active Active
- 2015-12-03 SI SI201531553T patent/SI3230298T1/sl unknown
- 2015-12-03 PL PL15804128T patent/PL3230298T3/pl unknown
- 2015-12-03 MY MYPI2017702051A patent/MY194002A/en unknown
- 2015-12-03 LT LTEP15804128.5T patent/LT3230298T/lt unknown
- 2015-12-03 CN CN201580018026.1A patent/CN106164079B/zh active Active
- 2015-12-03 MA MA41134A patent/MA41134B1/fr unknown
- 2015-12-07 TW TW104140978A patent/TWI733656B/zh active
-
2016
- 2016-07-11 US US15/207,338 patent/US10040815B2/en active Active
-
2017
- 2017-03-20 IL IL251285A patent/IL251285B/en unknown
- 2017-06-05 CL CL2017001426A patent/CL2017001426A1/es unknown
- 2017-06-07 PH PH12017501061A patent/PH12017501061B1/en unknown
-
2018
- 2018-04-16 HK HK18104912.7A patent/HK1245764A1/zh unknown
- 2018-07-02 US US16/025,170 patent/US10618929B2/en active Active
-
2020
- 2020-04-13 US US16/847,552 patent/US11180525B2/en active Active
-
2021
- 2021-03-17 HR HRP20210454TT patent/HRP20210454T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
MA37942B1 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA42972B1 (fr) | Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale | |
FR3028762B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
MA38591A1 (fr) | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
MX2022005912A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
MA35887B1 (fr) | Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2 | |
MA39153A1 (fr) | Nouveaux composés hétérocycliques |